IDiyas

For the Inventor, By the Inventor

Newark, DE, United States of America

Chao Qi

USPTO Granted Patents = 16 

 

Average Co-Inventor Count = 7.2

ph-index = 4

Forward Citations = 65(Granted Patents)


Location History:

  • Newark, DE (US) (2020 - 2024)
  • Wilmington, DE (US) (2024)

Company Filing History:

goldMedal16 out of 665 
 
Incyte Corporation
 patents

Years Active: 2020-2025

Loading Chart...
Loading Chart...
16 patents (USPTO):
1. 12466822 - Heterocyclic compounds as immunomodulators (2025-11-11),
2. 12441742 - Naphthyridine compounds as inhibitors of KRAS (2025-10-14),
3. 12441731 - Pyrazolopyrimidine compounds and uses thereof (2025-10-14),
4. 12378243 - Quinoline compounds as inhibitors of KRAS (2025-08-05),
5. 12083124 - Bicyclic heterocycles as FGFR inhibitors (2024-09-10),
6. 12077539 - Imidazole and triazole KRAS inhibitors (2024-09-03),
7. 12060433 - CD73 inhibitor and A2A/A2B adenosine receptor inhibitor combination therapy (2024-08-13),
8. 11999740 - Fused pyrazine derivatives as A2A / A2B inhibitors (2024-06-04),
9. 11939328 - Quinoline compounds as inhibitors of KRAS (2024-03-26),
10. 11673894 - Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors (2023-06-13),
11. 11607416 - Bicyclic heterocycles as FGFR inhibitors (2023-03-21),
12. 11591329 - Bicyclic heterocycles as FGFR inhibitors (2023-02-28),
13. 11339149 - Heterocyclic compounds as immunomodulators (2022-05-24),
14. 11161850 - Fused pyrazine derivatives as A2A / A2B inhibitors (2021-11-02),
15. 11111247 - Pyrazolopyrimidine compounds and uses thereof (2021-09-07),

Title: Chao Qi: Innovator in Pharmaceutical Compounds

Introduction

Chao Qi is a prominent inventor based in Newark, DE (US), known for his significant contributions to the field of pharmaceuticals. With a total of 15 patents to his name, he has made remarkable strides in developing compounds that target critical pathways in cancer treatment.

Latest Patents

Among his latest innovations are two notable patents. The first patent involves naphthyridine compounds that serve as inhibitors of KRAS. These compounds are designed to inhibit KRAS activity and are useful in treating, preventing, or ameliorating diseases associated with KRAS activity, such as cancer. The second patent focuses on pyrazolopyrimidine compounds, which inhibit ALK2 and FGFR activities. These compounds also hold promise in treating diseases related to these pathways, particularly cancer.

Career Highlights

Chao Qi is currently employed at Incyte Corporation, where he continues to advance his research and development efforts. His work has been instrumental in creating innovative solutions for complex medical challenges.

Collaborations

Chao has collaborated with notable colleagues, including Wenqing Yao and Liangxing Wu, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

Chao Qi's work exemplifies the impact of innovative thinking in the pharmaceutical industry. His patents not only reflect his expertise but also his commitment to improving cancer treatment options.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…